The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 3 years in the treatment of knee osteoarthritis. A prospective multicentre, international, double-blind, placebo-controlled study.

Trial Profile

The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 3 years in the treatment of knee osteoarthritis. A prospective multicentre, international, double-blind, placebo-controlled study.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2018

At a glance

  • Drugs Strontium ranelate (Primary)
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms POLKA; SEKOIA
  • Sponsors Servier
  • Most Recent Events

    • 22 Apr 2018 Results (n=1206) assessing data from follow-up study planned over 5-year, conducted in patients with a primary knee osteoarthritis having participated in the previous CL3-12911-018 study, were presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 05 Apr 2014 Results of an analysis of the placebo arm presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 05 Apr 2014 Results for the effect of meniscal extrusion and bone marrow lesions on response to strontium ranelate presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top